More than half of young adults between ages 18 and 39 with a cancer diagnosis reported problems with sexual function, according to a 2-year longitudinal study.
An integral part of a treatment plan for managing sexual dysfunction in women is the use of hormonal and pharmaceutical agents, a variety of which are available.
A stepwise approach ensures that all the potential issues and needs affecting a women’s sexual dysfunction are addressed prior to initiating management strategies.
Learn about the prevalence of HSDD and hear from Key Opinion Leaders about its effect on premenopausal women.
For particular groups of women, reluctance to talk about sexual difficulties may be enhanced by perceived societal judgements and misconceptions.
Female sexual dysfunction is not rare. In the United States, 44% of women are reported to experience some form of sexual dysfunction and 12% of these women report distress associated with dysfunction. Despite this high prevalence, many women never talk to their providers about their sexual difficulties or concerns and many providers fail to broach the topic with their patients.
An algorithm for determining whether a woman has female sexual dysfunction and which one she may have.
Despite its prevalence and adverse effect on women’s quality of life, female sexual dysfunction is often not addressed for a myriad of reasons.
Small studies suggest effective strategies, but more trials are needed.
A look at the pros and cons of this new drug for women with low sexual desire.